Protagenic Therapeutics, Inc.
PTIX
$1.84
-$0.05-2.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 840.60K | 814.30K | 338.40K | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 1.11M | 1.21M | 355.40K | ||
| Operating Income | -1.11M | -1.21M | -355.40K | ||
| Income Before Tax | -869.50K | -5.06M | -584.90K | ||
| Income Tax Expenses | -- | -- | -2.50K | ||
| Earnings from Continuing Operations | -869.50K | -5.06M | -582.40K | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -869.50K | -5.06M | -582.40K | ||
| EBIT | -1.11M | -1.21M | -355.40K | ||
| EBITDA | -1.10M | -1.20M | -- | ||
| EPS Basic | -0.47 | -1.37 | -0.11 | ||
| Normalized Basic EPS | -0.29 | -0.85 | -0.07 | ||
| EPS Diluted | -0.47 | -1.37 | -0.11 | ||
| Normalized Diluted EPS | -0.29 | -0.85 | -0.07 | ||
| Average Basic Shares Outstanding | 1.85M | 3.70M | 5.40M | ||
| Average Diluted Shares Outstanding | 1.85M | 3.70M | 5.40M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||